Last reviewed · How we verify
UCB SA — Portfolio Competitive Intelligence Brief
UCBJY (OTC)
12 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Kygevvi | DOXECITINE | marketed | Other | 2025-01-01 | ||
| Kygevvi | DOXRIBTIMINE | marketed | Other | 2025-01-01 | ||
| Bimzelx | BIMEKIZUMAB | marketed | Interleukin-17A | Immunology | 2021-01-01 | |
| Fintepla | FENFLURAMINE | marketed | fenfluramine | Alpha-1B adrenergic receptor | Metabolic | 2020-01-01 |
| Briviact | BRIVARACETAM | marketed | Synaptic vesicle glycoprotein 2A | Metabolic | 2016-01-01 | |
| Cimzia | CERTOLIZUMAB PEGOL | marketed | Tumor Necrosis Factor Blocker [EPC] | TNFα | Oncology | 2008-01-01 |
| Neupro | ROTIGOTINE | marketed | Nonergot Dopamine Agonist [EPC] | dopamine receptors | Neuroscience | 2007-01-01 |
| Xelstrym | dexamfetamine | marketed | Central Nervous System Stimulant [EPC] | Sodium-dependent noradrenaline transporter | Nephrology | 1955-01-01 |
| Amphetamine Sulfate | amfetamine | marketed | Central Nervous System Stimulant | Sodium-dependent dopamine transporter | Metabolic | 1955-01-01 |
| Vimpat | lacosamide | marketed | Dihydropyrimidinase-related protein 2, Carbonic anhydrase 1, Carbonic anhydrase 12 | Neuroscience | ||
| BIMZELX | BIMEKIZUMAB-BKZX | marketed | Interleukin-17A, Interleukin-17F, Interleukin-17AF | Immunology | ||
| RYSTIGGO | ROZANOLIXIZUMAB-NOLI | marketed | Neonatal Fc Receptor Blocker [EPC] | IgG receptor FcRn large subunit p51 | Other |
Therapeutic area mix
- Metabolic · 3
- Other · 3
- Immunology · 2
- Neuroscience · 2
- Nephrology · 1
- Oncology · 1
Recent regulatory actions (last 90 days)
- — Briviact · FDA · approved · US
- — Briviact · FDA · approved · US
- — Briviact · FDA · approved · US
- — Briviact · FDA · approved · US
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Amphetamine Sulfate · 10086087 · US
- — Amphetamine Sulfate · 8337890 · US
- — Amphetamine Sulfate · 9675704 · US
- — Amphetamine Sulfate · 9675703 · US
- — Amphetamine Sulfate · 8883217 · US
- — Amphetamine Sulfate · 8747902 · US
- — Amphetamine Sulfate · 8597684 · US
- — Amphetamine Sulfate · 8062667 · US
- — Xelstrym · 8846100 · US
- — Amphetamine Sulfate · 8846100 · US
- — Amphetamine Sulfate · 8709491 · US
- — Amphetamine Sulfate · 9017731 · US
- — Amphetamine Sulfate · 9265737 · US
- — Xelstrym · 9456993 · US
- — Xelstrym · 9474722 · US
- — Amphetamine Sulfate · 11590228 · US
- — Amphetamine Sulfate · 11160772 · US
- — Amphetamine Sulfate · 10441554 · US
- — Amphetamine Sulfate · 11590081 · US
- — Vimpat · 11883374 · Formulation · US
- — Vimpat · 11337943 · Formulation · US
- — Vimpat · 12042474 · Formulation · US
- — Xelstrym · 11559501 · US
Competitive overlap (companies sharing drug classes)
- · 3 shared drug classes
- Azurity · 1 shared drug class
- COHERUS BIOSCIENCES INC · 1 shared drug class
- Caraco · 1 shared drug class
- Centocor Ortho Biotech Inc · 1 shared drug class
- Hikma · 1 shared drug class
- Immunex · 1 shared drug class
- Impax Labs · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for UCB SA:
Cite this brief
Drug Landscape (2026). UCB SA — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ucb. Accessed 2026-05-13.